After a flat first-half efficiency, tonic and mixer producer Fever-Tree grew its full-year income by 2%, however the UK remained in decline.
UK-based Fever-Tree offered its full-year gross sales efficiency for 2025 in a pre-close buying and selling replace printed yesterday (29 January). The primary half of the 12 months noticed the group file stagnant outcomes, with the US serving to to offset a difficult UK – Fever-Tree’s second-biggest market after the States.
The group’s complete income final 12 months grew by 2% to £375.3 million (US$516.5m), pushed by progress within the US and a double-digit acquire within the rest-of-the-world (ROW) area.
Fever-Tree struggled in its house market with UK income falling by 2% to £108.4m (US$149.2m), however famous that buying and selling had improved within the second half of the 12 months.
Its UK efficiency was led by the ‘strong’ off-trade, with progress coming from past its tonics, helped by the group’s premium comfortable drinks line.
The US grew by 3% to £131.9m (US$181.7m) whereas the ROW area soared by 17% to £37.7m (US$51.9m), boosted by Australia, New Zealand and Canada.
In January 2025, Fever-Tree agreed to promote an 8.5% stake to brewing large Molson Coors for £71m (US$88.4m) to “take the model to the following degree” within the US.
Fever-Tree CEO Tim Warrillow stated the enterprise made “wonderful progress” final 12 months.
“Our partnership with Molson Coors within the US is progressing properly, and the momentum behind the model is very encouraging, giving us confidence within the rising alternative in our largest market as execution strikes past the transition section.”
Broadening past tonic
In the meantime, full-year income for the Fever-Tree model in Europe was up by 2% to £94.7m (US$130.4m) after a ‘robust efficiency’ in France and Benelux.
“Throughout all our markets, we’re persevering with to construct momentum as we broaden Fever-Tree past tonic, positioning the model as not solely the premium mixer but additionally the premium comfortable drink of selection,” Warrillow added.
“We’re uniquely positioned to unlock the expansion alternatives afforded by the buyer developments in direction of moderation, premiumisation and longer, lighter serves.
“With thrilling advertising campaigns and a robust innovation pipeline, delivered by our passionate staff, I’m assured we are going to drive robust progress in 2026 and past.”
Fever-Tree famous that the transition into Molson Coors’ distribution community within the US, alongside an ‘upweighted advertising funding’, would result in a ‘robust platform’ for the 12 months forward.
In September 2025, Fever-Tree famous that its £100m (US$135.8m) share buyback programme was progressing properly. The corporate beforehand introduced it could prolong the scheme by an extra £30m (US$40.7m), with the newest buying and selling replace confirming it could start in February 2026.
The group additionally said that it could comfortably meet its present 2026 market expectations.
Fever-Tree intends to announce its preliminary outcomes on 24 March 2026, when particulars of its second-half efficiency from final 12 months are anticipated.
Associated information
Fever-Tree posts flat H1 gross sales
Fever-Tree: US tariffs current no headwinds
Fever-Tree gross sales soar in US as UK declines
